In Saudi Arabia, with over 32 million people and a growing healthcare industry, Admedus is now approved to sell their CardioCel biomaterial for heart valve repair surgeries and expand their Middle East presence. Admedus now sells CardioCel in many countries around the world and includes 135 medical centres, but Saudi Arabia is an important market for them since cardiovascular disease is the main cause of death in the country. They partnered with Genpharm for this expansion which is already active in Saudi Arabia and they are focusing on pediatric cardiac care first. The expansion is projected to keep Admedus on track for their anticipated $21 million revenue for the year. Wayne Paterson, CEO, told Proactive Investors, “This is the most significant approval for Admedus and our partners Genpharm in this key strategic region.”
Latest article
Bio-hybrid robot made from langoustine shells works like arcade claw crane
In Switzerland, scientists at École Polytechnique Fédérale de Lausanne have converted shellfish shells into claws that grip, not unlike the prize-filled claw machines found...
Holy Carp! makes waves as biodegradable single-use soy sauce alternative
In Australia, design studios Heliograf and Vert Design have jointly developed a biodegradable alternative to whimsical—but polluting—plastic fish-shaped soy sauce containers often seen with...
Pineapple hair ties win Fowler Business Concept Challenge
In California, a University of San Diego graduate student has won a $15,000 scholarship to advance her pineapple leaf hair ties.
Sage Dobby, who...